Second Sight Medical Products develops, manufactures and markets implantable visual prosthetics that deliver artificial vision to blind individuals. Co. is developing the Orion® Visual Cortical Prosthesis System, an implanted cortical stimulation device which provides artificial vision to individuals who are blind due to a range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Co.'s commercially approved product, the Argus® II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, a hereditary disease that causes a progressive degeneration of the light-sensitive cells of the retina. We show 38 historical shares outstanding datapoints in our coverage of EYES's shares outstanding history.
Understanding the changing numbers of EYES shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like EYES versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching EYES by allowing them to research EYES shares outstanding history
as well as any other stock in our coverage universe. |
Free EYES Email Alerts:
Video: Shares Outstanding Importance
